NHP study assigned to NIH,resu

Like
Comment
Favorite

且听风吟云起
2020-08-20

NHP study assigned to NIH,results in late Q3 2020 will be a positive catalyst?

Vaxart Positioned to Further Advance Oral COVID-19 Vaccine; Analyst Says ‘Buy’

In the race to develop a COVID-19 vaccine, the contenders aren’t about to cross the finish line just

Vaxart Positioned to Further Advance Oral COVID-19 Vaccine; Analyst Says ‘Buy’

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":970417077,"tweetId":"970417077","gmtCreate":1597854146799,"gmtModify":1705056311410,"author":{"id":3535919852177389,"authorId":3535919852177389,"authorIdStr":"3535919852177389","name":"且听风吟云起","avatar":"https://static.tigerbbs.com/1f99ccba0b1f951a039f14308c54b3cc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>NHP study assigned to&nbsp;NIH,results in late Q3 2020 will&nbsp;be a positive catalyst?</p></body></html>","htmlText":"<html><head></head><body><p>NHP study assigned to&nbsp;NIH,results in late Q3 2020 will&nbsp;be a positive catalyst?</p></body></html>","text":"NHP study assigned to NIH,results in late Q3 2020 will be a positive catalyst?","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/970417077","repostId":2059655685,"repostType":2,"repost":{"id":"2059655685","pubTimestamp":1597354541,"share":"https://www.laohu8.com/m/news/2059655685?lang=&edition=full","pubTime":"2020-08-14 05:35","market":"us","language":"en","title":"Vaxart Positioned to Further Advance Oral COVID-19 Vaccine; Analyst Says ‘Buy’","url":"https://stock-news.laohu8.com/highlight/detail?id=2059655685","media":"TipRanks","summary":"In the race to develop a COVID-19 vaccine, the contenders aren’t about to cross the finish line just","content":"<div>\n<p>In the race to develop a COVID-19 vaccine, the contenders aren’t about to cross the finish line just yet. As the deadly virus resurfaces in several countries, the world is anxiously waiting to see ...</p>\n\n<a href=\"https://finance.yahoo.com/news/vaxart-positioned-further-advance-oral-213541322.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart Positioned to Further Advance Oral COVID-19 Vaccine; Analyst Says ‘Buy’</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart Positioned to Further Advance Oral COVID-19 Vaccine; Analyst Says ‘Buy’\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-08-14 05:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/vaxart-positioned-further-advance-oral-213541322.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In the race to develop a COVID-19 vaccine, the contenders aren’t about to cross the finish line just yet. As the deadly virus resurfaces in several countries, the world is anxiously waiting to see ...</p>\n\n<a href=\"https://finance.yahoo.com/news/vaxart-positioned-further-advance-oral-213541322.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/X4GsvGURtg336sSeiWECEw--~B/aD00Nzc7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/7Hzd3Rvq0a8slJ1OivQydw--~B/aD00Nzc7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en-US/tipranks_452/765e06e5db0f132d543d4bdcd9d5f1ec","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://finance.yahoo.com/news/vaxart-positioned-further-advance-oral-213541322.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2059655685","content_text":"In the race to develop a COVID-19 vaccine, the contenders aren’t about to cross the finish line just yet. As the deadly virus resurfaces in several countries, the world is anxiously waiting to see which name will be the first to bring the coveted solution to market. Already underway for months now, it’s still anyone’s game in this battle of the ages.Who is emerging as a likely winner? If you ask 5-star analyst Vernon Bernardino, of H.C. Wainwright, of the 165-plus vaccine candidates (38 in clinical-stage testing) in development, Vaxart’s (VXRT) chances are looking pretty good.Based on the company’s Q2 2020 corporate update, it has reached multiple milestones that position it at the front of the pack. That being said, the analyst cites one accomplishment in particular as deserving of a major shoutout.Bernardino believes its selection to take part in a non-human primate (NHP) challenge study organized and funded by Operation Warp Speed (OWS) is the most “notable” of these milestones. Highlighting the candidate’s “broad potential” in the battle against the virus, the analyst argues the Street might just be underestimating the role it could play.Expounding on this, the H.C. Wainwright analyst stated, “...our positive view of Vaxart’s oral COVID-19 vaccine program advancing was bolstered by its selection for OWS participation, as this, in our opinion, represents recognition by BARDA that oral vaccines tested by Vaxart for other infectious diseases, such as influenza, norovirus and respiratory syncytial virus (RSV), point to an oral vaccine as a potentially important approach to vaccinating what is likely to be more than 100 million people in the U.S., and perhaps billions of people globally, most of which have no existing immunity to SARS-CoV-2.”The implications of the OWS selection go even further. NHPs are a rare resource for conducting preclinical studies, with only seven primate research centers able to perform NHP studies. In addition, the number of subjects is limited and the waiting lists are long.Given that the task of conducting the NHP challenge study has been assigned to the U.S. National Institutes of Health (NIH), it’s unclear what the timeline for completion and release of results will be.Nonetheless, Bernardino remains confident in VXRT’s prospects. “...in line with the pace of progression of competitor COVID-19 vaccine candidates, we expect the NHP study with Vaxart’s vaccine to be given high priority and be conducted quickly. We look for results in late Q3 2020 to be a positive catalyst,” he explained.Accordingly, Bernardino keeps a Buy rating on the stock. The positive assessment also warrants a substantial increase to the price target, which moves from $7 to $17. This target suggests shares could jump 87% in the year ahead. (To watch Bernardino’s track record, click here)VXRT has kept a relatively low profile, as only one other analyst has thrown an opinion into the mix. The additional bullish call means that the stock gets a Moderate Buy consensus rating. At $19.50, the average price target is more aggressive than Bernardino’s and implies 105% upside potential. (See Vaxart stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1},"isVote":1,"tweetType":1,"viewCount":158,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":65,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}